http://www.oncolink.org/whatsnew/ OncoLink - What's New this Week Sun, 19 May 2013 04:40:40 GMT http://www.oncolink.org/types/article1.cfm?id=9656 BRCA1 and BRCA2 is short for breast cancer susceptibility gene 1 and breast cancer susceptibility gene 2. The BRCA1 and BRCA2 genes are present in all individuals. Learn more about BRCA1 and BRCA2 now. Tue, 14 May 2013 04:00:00 GMT http://www.oncolink.org/blogs/index.php/2013/04/answers-to-your-nutrition-and-diet-questions/ Are you confused by all the information on cancer and nutrition; what to eat and what to avoid? The program reviews the current nutritional information and guidelines for cancer patients and survivors. Did you miss our webinar? Listen and watch the archive. Wed, 08 May 2013 04:00:00 GMT http://www.oncolink.org/treatment/article.cfm?c=171&id=580 This plant’s extract is often used by people with cancer in an effort to boost the immune system and treat side effects of cancer treatment. Fri, 03 May 2013 04:00:00 GMT http://www.oncolink.org/blogs/index.php/2013/04/after-breast-cancer-survivor-education-webchat/ Watch and listen to the archive of this webinar with Dr. Schmitz, Principal Investigator on the groundbreaking PAL trial, which demonstrated that exercise and weight training, is safe for breast cancer survivors, and decreased the risk of developing lymphedema. Addresses issues that commonly affect breast cancer survivors and explore ways to manage these concerns. Fri, 03 May 2013 04:00:00 GMT http://www.oncolink.org/resources/article1.cfm?id=1100 New Oncology Medical Minute. Non-Hodgkin's lymphoma (NHL) is the most common hematologic malignancy in adults, and the sixth most common cancer diagnosed in the United States each year. Fri, 03 May 2013 04:00:00 GMT http://www.oncolink.org/treatment/article.cfm?c=154&id=579 Stereotactic radiation, often referred to as stereotactic body radiation therapy (SBRT), stereotactic ablative radiotherapy (SABR) or stereotactic radiosurgery (SRS), is a form of radiation therapy that very precisely delivers a high dose of radiation to a tumor. Tue, 30 Apr 2013 04:00:00 GMT http://www.oncolink.org/resources/article.cfm?c=412&id=1097 This continuing education activity is designed for nurses and nurse practitioners in clinical practice to learn about the assessment, prevention and control of chemotherapy-induced nausea and vomiting (CINV). This activity has been approved for 1.0 contact hour. Mon, 22 Apr 2013 04:00:00 GMT http://www.oncolink.org/treatment/article.cfm?c=143&id=578 Kadcyla™ is a monoclonal antibody attached to a chemotherapy agent called maytansine (a microtubule inhibitor). Monoclonal antibodies are designed to target a specific type of cell – in this case, a Her2- positive breast cancer cell. Fri, 19 Apr 2013 04:00:00 GMT http://www.oncolink.org/enews/o-pro/spring2013.html "O-Pro" is the e-newsletter for oncology professionals. We hope this newsletter will to keep you up to date on what's new and useful for your practice in oncology. Fri, 19 Apr 2013 04:00:00 GMT